リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

An autopsy case of primary gliosarcoma with multiple extracranial metastases: pathology after administration of bevacizumab and genetic profile

Sato, Yoshiki Deguchi, Shoichi Norose, Tomoko Oishi, Takuma Mitsuya, Koichi Sugino, Takashi Akiyama, Yasuto Nagashima, Takeshi Urakami, Kenichi Shimoda, Yuji Ohshima, Keiichi Hayashi, Nakamasa Yamaguchi, Ken 名古屋大学

2023.11

概要

Gliosarcoma (GS) is a rare primary malignant brain tumor corresponding to World Health
Organization grade 4.1 It accounts for less than 0.5% of all intracranial tumors and is estimated
to comprise 1.8%–2.4% of glioblastoma, IDH-wild-type (GB) cases.2-4 In terms of the histopathology of GS, as one of the morphological variants of GB, it features a biphasic pattern with
gliomatous and sarcomatous components.4 Metastasis of GS has been reported to occur at a rate
as high as 11%, which is much higher than that of GB.3,5,6 A few reports on the pathology of the
extracranial metastasis of GS have shown that metastatic lesions had a sarcomatous component
alone or a mixture of gliomatous and sarcomatous ones.5,6 Therefore, it is considered that GS
tends to disseminate hematogenously due to its mesenchymal sarcomatous component.
GS has been treated in the same manner as GB.3-5 Bevacizumab is frequently used for the
recurrence of GB. However, the efficacy of bevacizumab for GS or its metastatic lesions is
still poorly understood. The pathology after the administration of bevacizumab is also unclear,
especially in metastatic specimens.
Recent genetic studies have demonstrated that GS shares gene alterations that also function
as drivers of GB. It has been reported that somatic mutations, such as in TP53 and PTEN, are
found in both gliomatous and sarcomatous components.7-9 Germline mutations associated with
GB, such as in TP53 and NF1, have been reported,10 but few with GS.
In this report, we review an autopsy case of GS with multiple extracranial metastases treated
by bevacizumab, including the results of genetic analysis. This study was approved by the ethics
committee of Shizuoka Cancer Center (J2021-56-2021-2-3). ...

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1 Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous

System: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi:10.1093/neuonc/noab106.

2 Beaumont TL, Kupsky WJ, Barger GR, Sloan AE. Gliosarcoma with multiple extracranial metastases: case

report and review of the literature. J Neurooncol. 2007;83(1):39–46. doi:10.1007/s11060-006-9295-x.

3 Dawar R, Fabiano AJ, Qiu J, Khushalani NI. Secondary gliosarcoma with extra-cranial metastases: a report

and review of the literature. Clin Neurol Neurosurg. 2013;115(4):375–380. doi:10.1016/j.clineuro.2012.06.017.

4 Zhang Y, Ma JP, Weng JC, et al. The clinical, radiological, and immunohistochemical characteristics

5 6 7 8 9 10 11 12 13 14 and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study. Neurosurg Rev.

2021;44(2):1003–1015. doi:10.1007/s10143-020-01285-4.

Choi MG, Lee JH, Lee MS, Suh SJ, Lee YS, Kang DG. Primary gliosarcoma with extracranial metastasis.

Brain Tumor Res Treat. 2020;8(1):53–56. doi:10.14791/btrt.2020.8.e9.

Ramos R, Morais N, Silva AI, Almeida R. Gliosarcoma with neuroaxis metastases. BMJ Case Rep.

2015;2015:bcr2015212970. doi:10.1136/bcr-2015-212970.

Biernat W, Aguzzi A, Sure U, Grant JW, Kleihues P, Hegi ME. Identical mutations of the p53 tumor suppressor gene in the gliomatous and the sarcomatous components of gliosarcomas suggest a common origin

from glial cells. J Neuropathol Exp Neurol. 1995;54(5):651–656. doi:10.1097/00005072-199509000-00006.

Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am

J Pathol. 2000;156(2):425–432. doi:10.1016/S0002-9440(10)64746-3.

Actor B, Ludwig Cobbers JMJ, Büschges R, et al. Comprehensive analysis of genomic alterations in

gliosarcoma and its two tissue components. Genes Chromosomes Cancer. 2002;34(4):416–427. doi:10.1002/

gcc.10087.

Fortunato JT, Reys B, Singh P, Pan E. Brainstem glioblastoma multiforme in a patient with NF1. Anticancer

Res. 2018;38(8):4897–4900. doi:10.21873/anticanres.12804.

Nagashima T, Yamaguchi K, Urakami K, et al. Japanese version of The Cancer Genome Atlas, JCGA,

established using fresh frozen tumors obtained from 5143 cancer patients. Cancer Sci. 2020;111(2):687–699.

doi:10.1111/cas.14290.

Sondka Z, Bamford S, Cole CG, Ward SA, Dunham I, Forbes SA. The COSMIC Cancer Gene Census:

describing genetic dysfunction across all human cancers. Nat Rev Cancer. 2018;18(11):696–705. doi:10.1038/

s41568-018-0060-1.

Georgescu M-M, Olar A. Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. Acta Neuropathol Commun. 2020;8(1):10. doi:10.1186/s40478-020-0889-x.

Srivastava H, Dewan A, Sharma SK, et al. Adjuvant radiation therapy and temozolomide in gliosarcoma:

Is it enough? Case series of seven patients. Asian J Neurosurg. 2018;13(2):297–301. doi:10.4103/ajns.

Nagoya J. Med. Sci. 85. 828–835, 2023

834

doi:10.18999/nagjms.85.4.828

Gliosarcoma with extracranial metastases

AJNS_151_16.

15 Azizi AA, Haberler C, Czech T, et al. Vascular-endothelial-growth-factor (VEGF) expression and possible

response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol.

2006;7(6):521–523. doi:10.1016/S1470-2045(06)70729-X.

16 DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer.

2007;109(5):813–819. doi:10.1002/cncr.22455.

17 Bogani G, Ditto A, Martinelli F, et al. Role of bevacizumab in uterine leiomyosarcoma. Crit Rev Oncol

Hematol. 2018;126:45–51. doi:10.1016/j.critrevonc.2018.03.019.

18 Ishida Y, Otsuka A, Kabashima K. Cutaneous angiosarcoma: update on biology and latest treatment. Curr

Opin Oncol. 2018;30(2):107–112. doi:10.1097/CCO.0000000000000427.

19 Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated

Kaposi’s sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012;30(13):1476–1483. doi:10.1200/

JCO.2011.39.6853.

20 Abdulla E, Hameed N, Arora R. A solitary case of gliosarcoma an indication for TP53 mutation analysis:

a non-concordant finding. Case report. Rom Neurosurg. 2021;35(2):210–214. doi:10.33962/roneuro-2021-034.

References End

Nagoya J. Med. Sci. 85. 828–835, 2023

835

doi:10.18999/nagjms.85.4.828

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る